XW033MA
XW033MA — Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10
Billable / specific codeICD-10-PCS
CMS abbreviated title: Introduce Emapalumab-lzsg in Periph Vein, Perc, New Tech 10
How XW033MA is built
Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.
- XSectionNew Technology — What family of procedure this is
- WBody systemWhich system it acts on
- 0Root operationThe objective — the verb of the procedure
- 3Body partThe specific site
- 3ApproachHow the site was reached
- MDeviceWhat was left in place, if anything
- AQualifierA further distinction where one applies
Codes near XW033MA
In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.
- XW033H6Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
- XW033H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033J7Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033K7Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033K9Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9
- XW033L6Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
- XW033L7Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033MAIntroduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW033N7Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033NAIntroduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW033P9Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9
- XW033PBIntroduction of Aztreonam-avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11
- XW033Q5Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
- XW033Q9Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
- XW033QBIntroduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11
- XW033R9Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9